Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEN-COV Treatment in Ambulatory COVID-19
NCT04425629Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of casirivimab, imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Started Jun 2020; status: terminated.
02
Drugs
casirivimabimdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04425629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425629.